10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||
| ||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBVIE INC. | |||
Ticker: ABBV Fiscal Year: 2022 | |||
Consolidated Statements of Earnings | |||
Period Ending Dec 31, 2022 10-K (Filed: Feb 17, 2023) | |||
| (In Millions) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
| Net revenues | $ 58,054 | 56,197 | 45,804 |
| Cost of products sold | 17,414 | 17,446 | 15,387 |
| Selling, general and administrative | 15,260 | 12,349 | 11,299 |
| Research and development | 6,510 | 6,922 | 6,379 |
| Acquired IPR&D and milestones | 697 | 1,124 | 1,376 |
| Other operating expense, net | 56 | 432 | 0 |
| Total operating costs and expenses | 39,937 | 38,273 | 34,441 |
| Operating earnings | 18,117 | 17,924 | 11,363 |
| Interest expense, net | 2,044 | 2,384 | 2,280 |
| Net foreign exchange loss | 148 | 51 | 71 |
| Other expense, net | 2,448 | 2,500 | 5,614 |
| Earnings before income tax expense | 13,477 | 12,989 | 3,398 |
| Income tax expense (benefit) | 1,632 | 1,440 | (1,224) |
| Net earnings | 11,845 | 11,549 | 4,622 |
| Net earnings attributable to noncontrolling interest | 9 | 7 | 6 |
| Net earnings attributable to AbbVie Inc. | 11,836 | 11,542 | 4,616 |
| Per share data | |||
| Basic earnings per share (in dollars per share) | 6.65 | 6.48 | 2.73 |
| Diluted earnings per share (in dollars per share) | 6.63 | 6.45 | 2.72 |
| Weighted-average basic shares outstanding (in shares) | 1,771 | 1,770 | 1,667 |
| Weighted-average diluted shares outstanding (in shares) | 1,778 | 1,777 | 1,673 |
| External Links | |
| ABBVIE INC. (ABBV) Fiscal Year 2022 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |